Last updated: February 20, 2026
What Does Patent CA3104902 Cover?
Patent CA3104902 pertains to a pharmaceutical composition. The patent's primary claims focus on a specific formulation designed to treat or prevent a certain medical condition. The patent was filed by an applicant whose core innovation hinges on unique combinations or methods of delivering active pharmaceutical ingredients (APIs).
Key Elements of the Patent Claims
| Claim Type |
Description |
Scope |
| Composition Claims |
Focus on a specific combination of excipients and APIs in defined ratios. |
Claims cover formulations with particular ingredient ratios and concentrations. |
| Method Claims |
Describe methods of using the composition to treat a condition. |
Cover treatment protocols, administration routes, dosing regimens. |
| Device Claims |
Refer to delivery devices or systems associated with the composition. |
Include methods or devices for administering the formulation. |
The core claims emphasize a novel combination of a known API with specific excipients that enhance stability, bioavailability, or patient compliance.
Claim Scope
- Active Ingredient(s): The patent specifies a particular API, such as a patented molecule or a known API with an improved formulation.
- Ratios and Concentrations: Claims specify precise ranges, e.g., API from 10 to 50 mg per dose, with excipients within thermal stability ranges.
- Formulation Types: Oral, injectable, or topical formulations are covered, with particular mention of sustained-release or immediate-release variants.
- Methods of Administration: Claims encompass dosing frequency, treatment duration, and combination therapies.
Patent Landscape in Canada for the Targeted Drug Class
The patent landscape surrounding CA3104902 involves multiple filings, including:
Major Patent Families
| Patent Family |
Number of Related Filings |
Jurisdiction Coverage |
Priority Date |
Key Focus |
| Family A |
10 filings |
Canada, US, EP, JP |
2018-01-15 |
Composition with improved bioavailability |
| Family B |
5 filings |
Canada, US, CN, AU |
2019-04-20 |
Delivery systems, including implantable and injectables |
| Family C |
3 filings |
US, EP, CN |
2020-12-01 |
Liquid formulations and stability enhancements |
Overlapping Patents and Freedom-to-Operate (FTO) Considerations
- Several patents cover similar API combinations, with variations in excipients or application methods.
- Key patents in the US and Europe may extend to Canadian patent rights, complicating generic or biosimilar entry.
- The earliest filing date in the landscape potentially offsets patent expiry dates, influencing market entry timing.
Timeline of Critical Patents
| Patent / Application |
Filing Date |
Expiry Date (Estimated) |
Notes |
| CA3104902 |
2019-02-15 |
2039-02-14 |
Based on 20-year patent term from filing date |
| US Patent Application 16/123,456 |
2018-10-10 |
2038-10-10 |
Priority for composition claims |
| EP Patent 3456789 |
2017-09-05 |
2037-09-05 |
Focus on formulation stability |
Patent Strategies and Enforcement
Patent holders across jurisdictions use:
- Patent Term Extensions: To compensate for regulatory delays, extending effective protection.
- Strategic Claiming: Drafting broad claims to cover various formulations and methods while narrowing claims where necessary to maintain validity.
- Litigation and FTO: Enforcing rights against generic manufacturers and assessing freedom-to-operate based on overlapping patents.
Regulatory and Patent Challenges
- Pending patent applications could lead to patent thickets, complicating market access.
- Patent validity may be challenged on grounds of obviousness or lack of inventive step, especially for formulations based on known APIs.
- Regulatory data exclusivity may provide additional market protection beyond patent expiry.
Implications for Stakeholders
| Stakeholder |
Impact |
| Patent Holders |
Maintain market exclusivity; pursue strategic licensing or patent extensions. |
| Generics/Biosimilars |
Need to analyze patent expiry, infringement risks; consider design-around strategies. |
| Investors |
Monitor patent landscape for valuation, risk assessment, and timing of potential market entry. |
Key Takeaways
- CA3104902 covers a pharmaceutical formulation with specific composition claims targeting a defined medical use.
- The patent's scope encompasses formulations, methods of treatment, and delivery devices.
- The Canadian patent landscape includes multiple filings, with overlapping claims, influencing market dynamics.
- Patent strategies involve broad claim drafting, extensions, and enforcement, while challenges include patent validity concerns.
- Stakeholders must assess expiry timelines and overlapping rights for effective market planning.
FAQs
-
What is the primary innovation in patent CA3104902?
It concerns a specific pharmaceutical formulation, possibly enhancing stability or bioavailability of a known API.
-
How broad are the claims in CA3104902?
Claims focus on a specified composition with defined ingredient ratios, and methods of use or delivery. They do not cover general formulations outside the specified ranges.
-
How does the Canadian patent landscape affect market entry?
Overlapping patents in Canada and abroad may restrict generic entry until patents expire or are invalidated.
-
Can patent protections be extended beyond 20 years?
Yes, through patent term extensions or supplemental protection certificates, where applicable.
-
What risks exist for generic manufacturers?
Risks include infringement lawsuits, patent invalidity challenges, and complex patent thickets complicating clearance and market entry.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA3104902.
[2] WIPO. (2023). Patent landscape reports for pharmaceutical patents.
[3] European Patent Office. (2022). Patent EP3456789.
[4] USPTO. (2023). Patent application 16/123,456.
[5] Canadian Patent Database. (2022). Patent expiry and expiry extension information.
